ArticleHeliyon2023

CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26).

Ji-Hea Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.